8-K filing — Sintx Technologies, Inc. (SINT)
Filed: 2026-08-13 AccNo: 0001493152-26-037613 Size: 236 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
SINTX Technologies Q2 EPS $(0.75) Misses $(0.66) Estimate, Sales $452.000K Beat $406.667K Estimate
SINTX Technologies (NASDAQ:SINT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.66) by 13.64 percent. This is a 17.58 percent increase over losses of $(0.91) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 8:09 PM
- Checked
- Aug 11, 2026, 8:09 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
SINTX Technologies Regains Nasdaq Compliance
SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a company focused on advanced silicon nitride materials and medical technologies, today announced that it received written notification
Read original at benzingaSINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program
SINTX Technologies has engaged Southern Metrics Consulting, led by veteran MedTech executive Chris Lyons (who serves on SINTX's Board since April 2025), to establish a Strategic Opportunity Management Program. The program will identify and evaluate strategic opportunities including partnerships, licensing, investments, joint ventures, and acquisitions to enhance stockholder value as the company transitions from development to commercial-stage operations.
Read original at globenewswire-inc